ProMIS Neurosciences
在场
ProMIS Neurosciences 是一家在股票代码 PMN (US) 下上市的公司。
高管
查看带有其 13 名主要高管的组织结构图
ProMIS Neurosciences 搜索最多的简介
- Neil Warma, Interim Chief Executive Officer and Director
- Eugene Williams, Chairman of the Board
- Patrick Kirwin, Director
高管在ProMIS Neurosciences变化
- Neil Warma 曾任 Independent Director, 现升职为 Interim Chief Executive Officer and Director (新闻发布的2024一月4号).
- Gail Farfel, Chief Executive Officer, 已经离开公司 (新闻发布的2024一月4号).
创建提醒
跟踪 ProMIS Neurosciences 的高管变动
生物技术
ProMIS Neurosciences 拥有 2,281 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Endeavor BioMedicines 刚刚宣布为 132 筹款数百万美元。 (公布2024四月25号).
- Metsera 刚刚宣布为 290 筹款数百万美元。 (公布2024四月23号).
- Histogen has filed for bankruptcy protection (公布2024四月19号).
生物技术 行业的其他推荐联系人
消息
ProMIS Neurosciences 的最新新闻稿
- ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
- ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
- ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
- ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
- ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
- Press Releases
- ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
- ProMIS Neurosciences, Inc. Announces Leadership Transition
- ProMIS Neurosciences Announces Publication on Novel Target for ALS
- ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
- View more press releases Close
通过电子邮件
